IMMUNE NETWORK RESEARCH (VSE:IMM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Kei Lu who wrote (104)	6/11/1999 9:44:00 AM
From: coolslug	Read Replies (1) of 134

Immune Network Research provides 1F7 progress; stock options granted Immune Network Research Ltd IMM Shares issued 20,370,452 Jun 10 close $0.26 Fri 11 Jun 99 News Release Mr. Allen Bain reports Immune Network Research wishes to update its shareholders on progress with the 1F7 AIDS antibody project. Further to news in Stockwatch Feb. 4, 1999, the company confirms that plasma samples from the phase II study of antibody 1F7 in primates have been submitted by Immpheron, Inc., the company's joint venture partner for this project, to the U.S. National Cancer Institute for testing of viral load. The company is currently carrying out a review of its scientific and commercial strategy for its 1F7 project. The company's corporate offices have been moved to the B.C. Research and Innovation Complex adjacent to the University of British Columbia. The new address and telephone number for the company is: Immune Network Research Ltd. 3650 Wesbrook Mall Vancouver, B.C. Canada V6S 2L2 Tel: (604) 222-5541 Fax: (604) 224-0540

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next